GS are correct. IMO.
Not to mention that, as noted in OP, CSL has significant competitive advantage over pricing. A brave move by Argenx.
You can also add to the equation the many, many, trials that CSL has underway some of which would more than compensate for the loses suggested.
GS are correct. IMO. Not to mention that, as noted in OP, CSL...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$279.56 |
Change
4.060(1.47%) |
Mkt cap ! $135.0B | |||
| Open | High | Low | Value | Volume |
| $277.50 | $280.00 | $276.24 | $195.9M | 703.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3495 | $279.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $279.61 | 243 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$279.62 |
Change
4.060 ( 1.50 %) |
||||
| Open | High | Low | Volume | ||
| $277.13 | $280.00 | $276.25 | 47852 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| CSL (ASX) Chart |